Table 4.
Annual reinfection rate of Helicobacter pylori
| Follow up period | No. of patients | Mean no. of H. pylori test | No. of reinfected patients | Patient-years (yr) | Annual reinfection rate (%) | |
|---|---|---|---|---|---|---|
| |
1 ≤ year <2 |
23 |
1.39 |
3 |
33.08 |
9.07 |
|
E |
2 ≤ year <3 |
18 |
2.22 |
3 |
42.25 |
7.10 |
|
B |
3 ≤ year <4 |
5 |
2.00 |
0 |
16.58 |
0 |
|
M |
4 ≤ year <5 |
8 |
2.63 |
0 |
34.67 |
0 |
|
T |
5 ≤ year <6 |
3 |
6.00 |
1 |
16.58 |
6.03 |
| |
6 ≤ year <7 |
1 |
5.00 |
0 |
6.5 |
0 |
| 7 ≤ year <8 |
1 |
5.00 |
0 |
7.5 |
0 |
|
|
Total |
59 |
2.05 |
7 |
157.17 |
4.45 |
|
| |
1 ≤ year <2 |
39 |
1.36 |
8 |
54.12 |
14.78 |
|
M |
2 ≤ year <3 |
37 |
2.05 |
8 |
91.75 |
8.72 |
|
E |
3 ≤ year <4 |
30 |
3.67 |
1 |
104.58 |
0.96 |
|
A |
4 ≤ year <5 |
10 |
3.80 |
2 |
43.33 |
4.62 |
| Total | 116 | 2.31 | 19 | 294.08 | 6.46 |
EBMT: esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d), metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d); MEA: moxifloxacin (400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.).